|
1
|
Hayes SC, Spence RR, Janda M, Eakin E, Shannon C, Goh J, Beesley VL, Vagenas D, Webb P, Coward J, Gordon LG, O'Neill H, Williams M, Rye S, Newton MJ, Baniahmadi S, Nascimento M, Nicklin J, Garret A, Obermair A. Pre-post feasibility trial of a telephone-delivered exercise intervention for patients during chemotherapy for recurrent ovarian cancer: the ECHO-R trial protocol. BMJ Open 2024; 14:e077158. [PMID: 38238061 PMCID: PMC10806642 DOI: 10.1136/bmjopen-2023-077158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Accepted: 12/11/2023] [Indexed: 01/23/2024] Open
Abstract
INTRODUCTION The benefits of exercise in reducing treatment-related morbidity and improving quality of life following a primary diagnosis of cancer have been well documented and have led to exercise being recommended by oncology societies for all people with a cancer diagnosis. However, these recommendations are derived from research typically involving cohorts with more common cancers and relatively good prognosis, such as breast and prostate. Evidence from these cancers may not apply to women with recurrent ovarian cancer. Therefore, the primary objective of this trial is to evaluate the feasibility and safety of a home-based, telephone-delivered exercise intervention for women undergoing chemotherapy for recurrent ovarian cancer. METHODS AND ANALYSIS The Exercise During Chemotherapy for Recurrent Ovarian Cancer (ECHO-R) trial is a single-arm, phase II, pre/postintervention trial of a 6-month, telephone-delivered exercise intervention (consistent with recommended exercise oncology prescription). The target sample size is 80 women who are currently undergoing (or are scheduled to receive) chemotherapy for recurrent ovarian cancer. Recruitment is through participating hospital sites in Queensland, Australia, or via self-referral. The exercise intervention comprises 12 telephone sessions over a 6-month period delivered by trial-trained exercise professionals and supplemented (where feasible) by five sessions face to face. Exercise prescription is individualised and works towards an overall goal of achieving a weekly target of 150 min of moderate-intensity, mixed-mode exercise. Assessments via self-administered survey and physical fitness and function tests occur at baseline and then at 6 and 9 months postbaseline. Data to inform feasibility and safety are recorded as case notes by the exercise professional during each session. ETHICS AND DISSEMINATION Ethics approval for the ECHO-R trial was granted by the Metro North Human Research Ethics Committee (HREC/2020/QRBW/67223) on 6 November 2020. Findings from the trial are planned to be disseminated via peer-reviewed publications and both national and international exercise and oncology conferences. TRIAL REGISTRATION NUMBER ACTRN12621000042842.
Collapse
Affiliation(s)
- Sandra C Hayes
- School of Health Sciences and Social Work, Menzies Health Institute Queensland, Griffith University, Nathan, Queensland, Australia
| | - Rosalind R Spence
- School of Health Sciences and Social Work, Menzies Health Institute Queensland, Griffith University, Nathan, Queensland, Australia
| | - Monika Janda
- Faculty of Medicine, Centre of Health Services Research, The University of Queensland, Brisbane, Queensland, Australia
| | - Elizabeth Eakin
- Faculty of Medicine, School of Public Health, The University of Queensland, Brisbane, Queensland, Australia
| | - Catherine Shannon
- Queensland Centre for Gynaecological Cancer Research, The University of Queensland, Herston, Queensland, Australia
| | - Jeffrey Goh
- Queensland Centre for Gynaecological Cancer Research, The University of Queensland, Herston, Queensland, Australia
| | - Vanessa L Beesley
- Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Dimitrios Vagenas
- School of Public Health and Social Work, Queensland University of Technology Faculty of Health, Kelvin Grove, Queensland, Australia
| | - Penny Webb
- Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Jermaine Coward
- Faculty of Medicine and ICON Cancer Care Centre, The University of Queensland, Brisbane, Queensland, Australia
| | - Louisa G Gordon
- Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Helene O'Neill
- Queensland Centre for Gynaecological Cancer Research, The University of Queensland, Herston, Queensland, Australia
| | - Merran Williams
- Queensland Centre for Gynaecological Cancer Research, The University of Queensland, Herston, Queensland, Australia
| | - Sheree Rye
- School of Health Sciences and Social Work, Menzies Health Institute Queensland, Griffith University, Nathan, Queensland, Australia
| | - Melissa J Newton
- School of Health Sciences and Social Work, Menzies Health Institute Queensland, Griffith University, Nathan, Queensland, Australia
| | - Sara Baniahmadi
- Queensland Centre for Gynaecological Cancer Research, The University of Queensland, Herston, Queensland, Australia
| | | | - James Nicklin
- Gynaecological Cancer, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
| | - Andrea Garret
- Queensland Centre for Gynaecological Cancer Research, The University of Queensland, Herston, Queensland, Australia
| | - Andreas Obermair
- Queensland Centre for Gynaecological Cancer Research, The University of Queensland, Herston, Queensland, Australia
| |
Collapse
|